The University Venture Fund (UVF) is the largest student-managed venture capital fund ($18.2M) in the United States.
Business Model: B2B Education
Revenue: $1.5M
Employees: 51-200
Address: 299 S Main St
City: Salt Lake City
State: UT
Zip: 84111
Country: US
The University Venture Fund (UVF) is the largest student-managed venture capital fund ($18.2M) in the United States. UVF is an independent venture fund that leverages the innovation of students from around the country. It promotes entrepreneurship by creating a forum of students to be directly involved in venture capital. Associates in the University Venture Fund are given a unique opportunity to work together with seasoned venture capitalists performing due diligence on start-up opportunities around the nation. UVF has invested alongside many nationally recognized venture funds including Draper Fisher Jurvetson, Kleiner Perkins Caufield &a; Byers, Benchmark Capital, Battery Ventures, Hummer Winblad Venture Partners, Opus Capital, Best-Buy Capital, etc. Major investors include Morgan Stanley and UBS. University Venture Fund invests in compelling new technologies, high growth opportunities and stable cash flowing businesses across a broad range of industries and sectors. This opportunistic investment approach allows UVF to take advantage of the latest trends and market dynamics and leverage the diverse backgrounds of our students. UVF only co-invests alongside other reputable institutional investors. Each year UVF hosts the University Private Equity Summit when business students from around North America gather to share best practices and learn from investment industry professionals. Visit www.uventurefund.com for more information.
Contact Phone:
+18013263590
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2006 | Merrimack Pharmaceuticals | Venture Round | - |
2/2010 | TrustedID | Venture Round | - |
4/2009 | Alianza | Series A | 0 |
6/2007 | Daz 3d | Series A | 4.2M |
10/2012 | Workfront | Growth | 17M |
12/2004 | Barosense | Series B | 6.2M |
3/2022 | Beereaders | Seed Round | 0 |
7/2009 | Control4 | Venture Round | 17.3M |
2/2009 | Transpond | Series A | 4.1M |
4/2011 | Veritract | Series A | 819.5k |
5/2007 | Ancora Pharmaceuticals | Series A | - |
8/2011 | Catheter Connections | Venture Round | 0 |
1/2019 | Recyclops | Convertible Note | 0 |
12/2018 | GoReact | Venture Round | 0 |
3/2012 | Coherex Medical | Series B | 0 |
11/1999 | Salus Therapeutics | Series A | 1M |
6/2007 | Advent Solar | Series D | 0 |
8/2009 | Barosense | Series D | 27M |
1/2015 | Lineagen | Series C | 0 |
4/2020 | Vutility | Series A | 11.8M |
12/2013 | Lineagen | Series C | 0 |
5/2021 | Algramo | Series A | 0 |
11/2006 | Socialtext | Venture Round | - |
3/2022 | Beereaders | Seed Round | 0 |
5/2021 | Algramo | Series A | 0 |
4/2020 | Vutility | Series A | 0 |
1/2019 | Recyclops | Convertible Note | 0 |
12/2018 | GoReact | Venture Round | 0 |
1/2015 | Lineagen | Series C | 0 |
12/2013 | Lineagen | Series C | 0 |
10/2012 | Workfront | Series C | 0 |
3/2012 | Coherex Medical | Series B | 0 |
8/2011 | Catheter Connections | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|